Legend Biotech Corporation (LEGN) News

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

In CARTITUDE-4, CARVYKTI® demonstrated clinically meaningful improvements in patient-reported outcomes when compared to standard of care The...

Monday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and more

U.S. index futures show remarkable stability in Monday’s pre-market trading, anticipating a shortened...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights

Legend Biotech Corporation (the “Company” or Legend Biotech), through its wholly owned subsidiary, Legend Biotech Ireland Limited, entered into...

Legend Biotech Subsidiary in License Agreement With Novartis

By Chris Wack Legend Biotech said its Legend Biotech Ireland subsidiary has entered into an exclusive, global license agreement for LB2102 with...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

The deal with Novartis seeks to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell...

Legend Biotech to Host Investor Conference Call on Third-Quarter Results

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel...

Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting

Two oral presentations and five poster presentations at ASH Annual Meeting exhibit new and updated data in the clinical development program for...

Form 144/A - Report of proposed sale of securities: [Amend]